Showing 7891-7900 of 9142 results for "".
- TARGET PharmaSolutions Launches Real-World Study to Advance the Understanding of AD and Other IMISCshttps://practicaldermatology.com/news/target-pharmasolutions-launches-target-derm-real-world-study-to-advance-the-understanding-of-atopic-dermatitis-and-other-immune-mediated-inflammatory/2459890/TARGET PharmaSolutions, Inc., has launched its latest large-scale observational study, TARGET-DERM (NCT03661866). The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis. TARGET-DERM&
- AAD Honors Philadelphia Physicians For Teamwork to Treat Patient with Leprosyhttps://practicaldermatology.com/news/aad-honors-philadelphia-physicians-for-teamwork-to-treat-patient-with-leprosy/2459891/The American Academy of Dermatology (AAD) has honored Carrie Kovarik, MD, FAAD, and Keith Hamilton, MD, as Patient Care Heroes for their collaboration to improve patient care. Both physicians teach and practice medicine at the Perelman School of Medicine at the University of Pennsylvania in Phila
- Physician Burnout Rates Fall Modestlyhttps://practicaldermatology.com/news/physician-burnout-rates-fall-modestly/2459892/The burnout rate among physicians in the United States has dropped, but there remains significant room for improvement, new data suggest. The burnout rate dropped modestly in 2017 from its peak in 2014. Current burnout rates are in line with 2011 levels. The triennial s
- Rodan & Fields Takes on Teen Acne with Spotlesshttps://practicaldermatology.com/news/rodan-fields-takes-on-teen-acne-with-spotless/2459898/Rodan & Fields is launching Spotless, a patent-pending teen and young adult acne solution. The company is also updating its Unblemish R
- Sienna Biopharmaceuticals: Promising Topline Results for SNA-001 for Hair Removalhttps://practicaldermatology.com/news/sienna-biopharmaceuticals-promising-topline-results-for-sna-001-for-hair-removal/2459899/Topline results from the pivotal trial of Sienna Biopharmaceuticals’ SNA-001 show that the topical agent in conjunction with an 810nm diode laser was statistically superior compared to vehicle plus laser. In the study involving 65 male and female patients with white, gray, blonde, light red
- Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rxhttps://practicaldermatology.com/news/applied-biology-to-enter-into-a-license-agreement-with-hairmore-for-novel-traction-alopecia-rx/2459904/Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group. When applied to the scalp, Applied Biology’s
- New from BD: Prefillable Glass Syringe for Viscous Solutionshttps://practicaldermatology.com/news/new-from-bd-prefillable-glass-syringe-for-viscous-solutions/2459910/BD (Becton, Dickinson and Company) has presented BD Hylok,its new glass pre-fillable syringe for the administration of viscous solutions such as hyaluronic acid dermal fillers, at Pharmapack 2019. BD Hylokis also the first glass pre-fillab
- Key West Bans Sunscreens with Oxybenzone and Octinoxatehttps://practicaldermatology.com/news/key-west-bans-sunscreens-with-oxybenzone-and-octinoxate/2459911/Following Hawaii’s lead, Florida’s Key West City Commission voted to ban the sale of products that contain oxybenzone or octinoxate — two chemicals in sunscreen that have been shown to wash off and potentially damage coral reefs. The ban takes effect in January 2021. Fir
- Biologics May Reduce Plaque Buildup in Psoriasis Patients' Arterieshttps://practicaldermatology.com/news/biologics-may-reduce-plaque-buildup-in-psoriasis-patients-arteries/2459913/Treating psoriasis with biologic drugs can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke, according to a study funded by the Natio
- Vyome Secures $22M to Advance Dermatology Pipelinehttps://practicaldermatology.com/news/vyome-secures-22m-to-advance-dermatology-pipeline/2459918/Vyome Therapeutics Inc., a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, closed $22 million in financing. The company says it plans to primarily use the funds to advance its lead molecule, VB 19